Heparin-Induced Trombocytopenia (HIT) is a serious and potentially fatal complication of patients on heparins. Its management is difficult and it can be more complicated in patients with cancer because of the hemorrhagic risk carried out by direct inhibitor of thrombin, the currently approved drug for HIT. At present, it is not clear whether cancer patients also have an increased risk of HIT. We describe the case of a patient with occult cancer at the moment of the index venous thrombosis, who developed Deep Vein Thrombosis (DVT) and concomitant HIT with thrombotic complications (recurrent controlateral venous thrombosis). The management of HIT was efficaciously based on the combined use of alternative antithrombotic regimens (Dermatan-Sulphate and Defibrotide), without an increased risk of bleeding. This case highlights the potential relationship between DVT, as first episode of an occult cancer, and the risk of developing HIT. The use of alternative antithrombotic therapy seems to be efficacious even in this high-risk cancer patient.
Heparin Induced Trombocytopenia (HIT) is a serious and potentially fatal complication of patients on heparins; the disease depends on an abnormal immune response of immunoglobins to PF4-heparin complex (1) (2) .
It has been postulated that medical patients treated with Low Molecular Weight Heparin (LMWH) carry a lower risk of HIT than surgical patients treated with Unfractionated Heparin (UFH) (1). However, new data have shown that, \ in medical patients receiving LMWH, the risk of developing HIT is about 1% (3) .
Although the relationship between Venous Thromboembolism (VTE) and cancer is well known (4), it is still unclear whether cancer patients also have an increased risk of HIT and/or whether its management can be more difficult than in patients without cancer. Nevertheless Opatmy et al (5) suggest that patients with cancer suffer significantly more HIT-related complications than those without.
We describe the case of a cancer patient who developed HIT after treatment with LMWH and RESULTS The platelet count sharply increased after 2 days (120.000 mm") (see Table I ); ELISA test for PF4-Heparin antibodies was highly positive for HIT. A few day later, while the patient was on DS on therapeutic range, she developed a second episode of DVT in the contra-lateral leg. We therefore decided to administer Defibrotide (200 mg intravenously 3
to INR values of 2.0-3.0). After 3 days, the patient developed thrombocytopenia (21.000/mm 3 ) (see Table  I ). HIT syndrome was therefore suspected, heparin was withdrawn and an ELISA test for the detection of Ig-PF4-heparin antibodies was performed. Alternative anti-thrombotic therapy with DS was initiated (i.v. 12 mg/ Kg/die according to maintain the aPTT ratio above 1.5) together with oral anticoagulants; this protocol was part of a clinical trial and the patient gave informed consent to participate in whom combined therapy of dermatan sulphate (DS) and Defibrotide was efficacious in controlling thromboembolic complications without increasing the risk of bleeding.
MATERIALS AND METHODS
A 74-year-old-white woman with a history of diabetes mellitus and hypertension was referred to the Cardioangiology Unit of University Hospital of Palermo for acute dyspnoea and chest pain; she had an episode of right leg pain, edema and functional impotence in the past month. On admission, the patient was tachypnoic and symptomatic for Deep Vein Thrombosis (DVT). Compression Ultra-Sonography (C-US) exam showed the non-compressibility of the popliteal and femoral veins of the right leg. The spiral Computed Tomography (CT) scan showed a sub-segmental pulmonary embolism of the lower segments of the right inferior lobe. Venous Thromboembolism (VTE) was diagnosed and the patients received subcutaneous LMWH (Enoxaparine 100 UI/Kg b.i.d.) and oral anticoagulants (Acenocumarol according Because of the history of recurrent venous thromboembolism and clinical presentation, we decided to screen the patient for occult cancer; the abdomen ultrasonography finding and elevated levels of carcioembryonic antigen, were suggestive of neoplasm of the gallbladder which was then confirmed by abdominal CT scan and biopsy. Since cancer was considered not resectable, we decided to perform retrograde endoscopic cholangiography for implementing palliative stent. Unfortunately, the patient died 3 months after diagnosis because of cancer complication; during that period, she did not experience any sign or symptom suggestive of recurrent VTE.
DISCUSSION
The relationship between venous thrombosis and cancer is well known; patients with idiopathic(extensive or bilateral) DVT have a high risk of subsequent overt malignancy in the years following the diagnosis (6) . HIT can be a serious complication ofheparin treatment, potentially affecting a great number of patients who receive unfractionated or LMWH. Little evidence suggests that cancer patients carry an increased risk of developing HIT during heparin treatment; this can have an important clinical impact, especially considering that long term heparin is starting to represent the treatment of choice for DVT in cancer.Although no extrapolation can be made to general condition on the basis of a single case report, our short report in the context of the available data concerning the complex relationship between cancer, venous thromboembolic events and HIT occurrence, could suggest some considerations: firstly, the occurrence ofHIT and the recurrence ofDVT, should encourage investigating an occult neoplasm (7-10); secondly are HIT and DVT prognosis indicators of cancer and what is the best therapeutic management of thromboembolism and thrombocitopaenia in cancer patients? The first issue could appear suggestive, but no data are currently available to sustain it. With regard to the second question, immediate cessation of heparin treatment is necessary when HIT develops. No study, to our knowledge, has evaluated the treatment of HIT in cancer patients, but Imberti et al (2) reported :m the use of dermatan sulfate (DS) in six patients with HIT and acute venous thromboembolism, with a deep vein catheter-related thrombosis in a child with acute leukemia, obtaining an effective arid safe anticoagulation and a rapid rise in the platelet count (11). Therefore, the use of DS should be considered in the treatment of thromboembolic complications during HIT. The stable anticoagulant effect of this agent and its low cost could result in it being favored over the alternative anticoagulant drugs currently used for HIT. Our patient then developed HIT on LMWH; this finding, even in cancer patients, is still debated. A recent investigation has shown that medical patients, treated with prophylactic or therapeutic doses of LMWH, can develop HIT in about 1% ofthe cases (4). These data are not negligible since a large number of patients receive LMWH for several purposes. Whether the presence of cancer had further increased the rate of HIT is still unknown. Finally, the use of alternative antithrombotic drugs, such as DS and Defibrotide, appeared to be safe and efficacious even in this high risk patient.
